Last updated: August 24, 2026
DIANEAL PD-2 with dextrose 2.5% in a plastic container is a legacy peritoneal dialysis solution marketed by Baxter’s former Kidney Care business, now operated by Vantive after Baxter completed its sale of the business to Carlyle in 2024. The product is an established, prescription dialysis fluid rather than a growth-stage pharmaceutical. Its commercial value comes from recurring treatment volume, manufacturing scale, sterile-fluid supply reliability and customer switching costs.
No product-level revenue, gross-margin or unit-volume disclosure is available for DIANEAL PD-2. Financial analysis therefore depends on the reported performance of the broader Kidney Care or Vantive business and on structural trends in peritoneal dialysis.
What is DIANEAL PD-2 with dextrose 2.5%?
DIANEAL PD-2 is a peritoneal dialysis solution containing dextrose at a 2.5% concentration. It is used in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis to remove excess fluid and metabolic waste through the peritoneal membrane.
The 2.5% dextrose formulation provides greater ultrafiltration than lower-dextrose solutions. The prescribing label warns that excessive use can cause dehydration, hypovolemia, hyperglycemia and electrolyte disturbances. Treatment selection depends on the patient’s fluid status, glucose tolerance, residual renal function and dialysis prescription.[1]
| Product characteristic |
DIANEAL PD-2, dextrose 2.5% |
| Therapeutic category |
Peritoneal dialysis solution |
| Active osmotic agent |
Dextrose |
| Dextrose concentration |
2.5% |
| Administration |
Intraperitoneal |
| Primary use |
Removal of excess fluid and metabolic waste |
| Dosage form |
Sterile dialysis solution |
| Container |
Plastic container |
| Manufacturer history |
Baxter Healthcare; Kidney Care business transferred to Vantive |
| Prescription status |
Prescription medical product |
| Product-level revenue disclosure |
Not separately reported |
DIANEAL products are supplied in multiple dextrose concentrations and container configurations. The plastic-container format is intended for sterile storage and connection to dialysis equipment. Compatibility with the patient’s transfer set and dialysis system is a practical purchasing consideration.
What is the FDA regulatory status of DIANEAL PD-2 2.5%?
DIANEAL PD-2 is an FDA-approved peritoneal dialysis solution marketed under a legacy new drug application framework. The FDA-approved labeling identifies the product as a peritoneal dialysis solution containing dextrose and electrolytes for intraperitoneal administration.[1]
The product does not have the regulatory profile of a new molecular entity. Its development and commercial position are based on an established dialysis modality, known ingredients and manufacturing controls for sterile solutions.
| Regulatory issue |
Assessment |
| FDA pathway |
Legacy NDA product |
| FDA-approved use |
Peritoneal dialysis |
| New chemical entity exclusivity |
Not applicable |
| Pediatric exclusivity |
No product-specific period identified |
| Orphan-drug exclusivity |
Not applicable |
| Biologic licensing |
Not applicable |
| Manufacturing controls |
Sterility, composition, container integrity and connection compatibility |
| Regulatory risk |
Supply, quality and manufacturing compliance rather than novel-clinical-data risk |
The product’s regulatory exposure is concentrated in manufacturing consistency, container integrity, sterility assurance, labeling, distribution and continuity of supply. A manufacturing deviation can have a direct clinical effect because patients may depend on daily dialysis fluid deliveries.
What is the Orange Book status of DIANEAL PD-2?
DIANEAL PD-2 is not generally treated as a product with a meaningful active Orange Book patent-exclusivity position. Its commercial protection is more likely to arise from manufacturing know-how, product quality systems, customer relationships, logistics and installed dialysis equipment than from unexpired composition-of-matter patents.
The FDA Orange Book lists approved drug products and certain patent and exclusivity information. Older dialysis solutions may have an approved NDA without a commercially material, unexpired patent listing that blocks competing products.[2]
| Exclusivity category |
Relevance to DIANEAL PD-2 |
| New chemical entity exclusivity |
None expected |
| New clinical investigation exclusivity |
No current product-specific period identified |
| Orphan exclusivity |
None |
| Pediatric exclusivity |
None identified |
| Listed composition patent |
No material active listing identified in the cited regulatory materials |
| Listed formulation patent |
No material active listing identified |
| Practical market protection |
Manufacturing, supply and clinical workflow |
This does not mean that every competing product can enter immediately. A competitor must produce a compliant sterile dialysis solution, obtain FDA authorization, qualify materials and packaging, establish manufacturing capacity and win approval from dialysis providers and purchasing organizations.
When does DIANEAL PD-2 lose exclusivity?
DIANEAL PD-2 does not have a conventional future patent-cliff date comparable to a branded small-molecule medicine with an active composition patent. The principal market-access issue is whether a competing manufacturer can commercialize an equivalent peritoneal dialysis solution and meet the required quality and supply standards.
The relevant commercial protection has likely existed for decades through a combination of:
- Established FDA authorization.
- Validated sterile-fluid manufacturing.
- Proprietary or operational knowledge involving formulation, packaging and distribution.
- Dialysis-clinic purchasing relationships.
- Patient and provider familiarity.
- Integration with home-dialysis equipment and transfer systems.
- High costs of production interruption and product qualification.
The absence of a clear patent expiry event reduces the probability of a single-day generic launch shock. It does not eliminate price pressure. Competitors can erode share through alternative peritoneal dialysis solutions, tenders, private-label arrangements or expanded production by existing suppliers.
What patents protect DIANEAL PD-2?
No active, product-defining composition-of-matter patent has been identified in the cited FDA materials for DIANEAL PD-2 with dextrose 2.5% in a plastic container. The product’s protection is better characterized as an operational and manufacturing moat than as a patent estate.
Potentially relevant intellectual-property categories include:
| IP category |
Potential relevance |
| Solution formulation |
Concentrations of dextrose, electrolytes, buffers and pH control |
| Container technology |
Plastic composition, multilayer construction and compatibility |
| Sterile manufacturing |
Filling, sealing, sterilization and contamination controls |
| Transfer systems |
Connectors, ports and administration components |
| Automated dialysis systems |
Cycler operation and disposable-set interfaces |
| Trade secrets |
Process parameters, validation data and quality systems |
| Trademarks |
DIANEAL and related product branding |
The most important IP risks are therefore likely to arise from packaging, connection systems, manufacturing processes or equipment integration rather than from the dextrose-containing solution itself.
How large is the peritoneal dialysis market?
Peritoneal dialysis is a recurring-use market with a smaller patient base than in-center hemodialysis but a high consumables requirement per treated patient. A patient using peritoneal dialysis can require repeated daily solution exchanges or automated cycler supplies, creating predictable demand for bags, tubing and related disposables.
Market growth is shaped by five factors:
- Growth in end-stage kidney disease.
- Greater use of home dialysis.
- Hospital and payer efforts to shift treatment away from facilities.
- Availability of trained caregivers and home support.
- Manufacturing capacity for dialysis fluids and equipment.
Peritoneal dialysis competes with in-center hemodialysis and home hemodialysis. Its advantages include treatment at home, reduced facility visits and greater scheduling flexibility. Its limitations include infection risk, storage requirements, training needs and the suitability of the patient’s peritoneal membrane.
The U.S. market has strong incumbent concentration. Baxter historically held a leading position in peritoneal dialysis, while Fresenius Medical Care has a major global dialysis business and supplies competing dialysis products and services. The competitive set also includes regional manufacturers, hospital suppliers and distributors.
Which companies compete with DIANEAL PD-2?
Vantive
Vantive owns the former Baxter Kidney Care business, including the peritoneal dialysis portfolio. Carlyle completed the acquisition from Baxter in 2024 for approximately $3.8 billion, creating an independent kidney-care company.[3]
Vantive’s commercial strengths include:
- A broad installed base of dialysis patients and cyclers.
- Established nephrology and clinic relationships.
- Global manufacturing and distribution.
- Recurring demand for dialysis fluids and disposable supplies.
- Cross-selling between dialysis solutions, cyclers and consumables.
Fresenius Medical Care
Fresenius Medical Care is the largest global dialysis-services company and also sells dialysis equipment, products and supplies. Its vertically integrated position gives it purchasing scale and clinical access. It competes with Baxter and Vantive in dialysis products, though the competitive relationship varies by geography and treatment setting.[4]
Regional and private-label suppliers
Regional producers can compete where local regulatory approval, lower manufacturing costs or public procurement contracts support entry. Their ability to challenge DIANEAL depends on sterile-fluid capacity, distribution reliability, product range and compatibility with local dialysis systems.
How does DIANEAL compare with competing dialysis solutions?
The most direct comparison is not between patented molecules. It is between dialysis systems, solution portfolios, equipment compatibility and total treatment cost.
| Factor |
DIANEAL PD-2 |
Competing PD solution |
| Dextrose concentration |
2.5% |
Often available in multiple concentrations |
| Primary commercial value |
Recurring fluid consumption |
Recurring fluid consumption |
| Clinical differentiation |
Limited at the base-solution level |
May involve buffers, electrolytes or packaging |
| Switching cost |
Moderate to high |
Depends on cycler and transfer-set compatibility |
| Patent dependence |
Low |
Generally low for legacy solutions |
| Supply-chain importance |
Very high |
Very high |
| Buyer priorities |
Quality, availability, price and compatibility |
Same |
| Main competitive risk |
Price and supply substitution |
Qualification and manufacturing barriers |
Clinicians can select different dextrose concentrations depending on ultrafiltration needs. A competitor does not necessarily need to duplicate every commercial feature of DIANEAL to exert pressure. It can target selected concentrations, hospital accounts or regional tenders.
What financial trajectory does DIANEAL PD-2 have?
DIANEAL PD-2 is likely a mature, recurring-revenue product with limited unit-price growth and relatively stable demand tied to the installed peritoneal-dialysis population. The product’s financial trajectory is driven by volume, pricing, production costs and portfolio retention rather than by new indications.
Baxter reported Kidney Care as a major business segment before the divestiture. The company’s annual reports describe Kidney Care as a global business covering peritoneal dialysis, hemodialysis and related products.[5] Baxter did not separately disclose revenue for the DIANEAL brand or for individual dextrose concentrations.
The product’s likely economic profile is:
| Financial driver |
Expected effect |
| Patient-volume growth |
Supports recurring demand |
| Home-dialysis adoption |
Positive for PD solution consumption |
| Price increases |
Can offset inflation and logistics costs |
| Plastic and resin costs |
Margin pressure |
| Sterile manufacturing costs |
Margin pressure and capacity constraints |
| Freight and warehousing |
Material because solutions are bulky and heavy |
| Product shortages |
Can reduce sales and damage customer retention |
| Competitor entry |
Pricing and share pressure |
| Equipment installed base |
Supports customer retention |
| Portfolio ownership transfer |
Changes reporting entity, not necessarily clinical demand |
The Carlyle transaction changed ownership and reporting structure rather than the underlying patient need for dialysis fluid. The main commercial question is whether Vantive can preserve Baxter’s scale, service levels and customer relationships while operating as a standalone company.
What revenue exposure does the product create for Vantive?
The product is part of a broader recurring-consumables model. Revenue exposure is tied to the number of patients using peritoneal dialysis, the number of exchanges per patient, solution concentration mix and channel pricing.
The product can generate attractive revenue visibility because treatment is continuous. A patient is not typically making a one-time purchase. Dialysis requires ongoing supplies, and the solution is consumed as part of each treatment cycle.
The financial risks are concentrated in:
- Reimbursement pressure from public and private payers.
- Hospital and dialysis-provider purchasing consolidation.
- Input-cost inflation.
- Freight and storage expense.
- Production outages.
- Regulatory remediation.
- Product recalls.
- Competitor substitution.
- Changes in dialysis modality.
A shift from peritoneal dialysis to in-center hemodialysis would reduce demand for PD fluid. A shift toward home-based care would support demand. The net effect depends on patient eligibility, reimbursement, physician practice and infrastructure.
What manufacturing and supply barriers protect DIANEAL?
Manufacturing capacity is a substantial barrier to entry. Peritoneal dialysis solutions are aqueous sterile products that require high-volume filling, validated sterilization or aseptic controls, container integrity testing and reliable distribution.
The products are also heavy and expensive to transport relative to their active pharmaceutical content. This creates a geographic advantage for manufacturers with plants near major markets and established logistics networks.
Key barriers include:
- Large-scale sterile-liquid facilities.
- Quality-system validation.
- Reliable plastic-container supply.
- High-volume filling and sealing.
- Microbiological control.
- Shelf-life validation.
- Regulatory inspection readiness.
- Regional warehouse capacity.
- Emergency supply planning.
- Compatibility with dialysis equipment.
These barriers reduce the likelihood of rapid entry by a conventional generic-drug company. They do not prevent competition from another dialysis specialist with existing sterile-fluid infrastructure.
What litigation and settlement risks affect DIANEAL PD-2?
No major current Paragraph IV litigation or product-specific patent-settlement event is identified for DIANEAL PD-2 in the cited sources. That outcome is consistent with the product’s age and limited apparent reliance on active patent exclusivity.
The more relevant legal risks are likely to involve:
- Manufacturing defects.
- Product contamination.
- Packaging or connector failures.
- Product recalls.
- Supply interruptions.
- Contract disputes with dialysis providers.
- Regulatory enforcement.
- Trade-secret or manufacturing-technology disputes.
- Competition involving dialysis equipment and disposable systems.
Because the product is a sterile medical solution used by vulnerable patients, quality and supply litigation can have greater commercial impact than a conventional patent case.
What generic launch risks exist for DIANEAL PD-2?
A generic or competing launch would probably occur through product authorization and commercial qualification rather than through a classic Paragraph IV challenge against a blocking patent.
| Launch scenario |
Commercial impact |
| Regional competitor enters with one concentration |
Local price pressure |
| Large dialysis supplier expands PD portfolio |
Meaningful account and share risk |
| Hospital tender favors lower-cost supplier |
Margin reduction |
| Competitor matches equipment compatibility |
Higher switching risk |
| Manufacturing shortage affects Vantive |
Rapid share loss and contractual exposure |
| Vantive secures supply and service advantage |
Stable share with moderate pricing pressure |
The highest-risk scenario is a competitor with both sterile-fluid manufacturing and a compatible dialysis-system ecosystem. A standalone solution supplier would face greater difficulty converting patients because dialysis products are embedded in clinical workflows and equipment systems.
What is the geographic coverage of DIANEAL PD-2?
DIANEAL has been commercialized across multiple international markets, subject to country-specific registrations, labeling and product configurations. Geographic performance depends on:
- Local approval status.
- Peritoneal-dialysis reimbursement.
- Import requirements.
- Availability of dialysis cyclers.
- Distribution infrastructure.
- Public procurement.
- Local manufacturing.
- Currency and freight costs.
The product’s global reach strengthens purchasing scale but increases exposure to foreign-exchange movements, trade restrictions, local quality requirements and regional supply disruptions.
Key Takeaways
- DIANEAL PD-2 with dextrose 2.5% is a mature peritoneal dialysis solution used for ultrafiltration and waste removal.
- The product is now associated with Vantive, following Carlyle’s acquisition of Baxter’s Kidney Care business in 2024.
- No product-level revenue or profit figures are publicly disclosed.
- The product does not appear to depend on a conventional active patent cliff or meaningful new-drug exclusivity period.
- Manufacturing scale, sterile-quality systems, distribution and equipment compatibility are the principal commercial barriers.
- Demand is recurring and linked to the number of peritoneal-dialysis patients and treatment exchanges.
- Home-dialysis growth supports demand, while modality shifts, reimbursement pressure and competitor supply can reduce it.
- The main legal risks are likely to involve manufacturing, product quality, supply and equipment compatibility rather than Paragraph IV patent litigation.
- Vantive’s ability to maintain supply reliability and customer relationships will determine the product’s financial trajectory more than patent duration.
FAQs About DIANEAL PD-2 2.5% in Plastic Containers
Is DIANEAL PD-2 2.5% a generic drug?
It is an established FDA-authorized peritoneal dialysis solution. Its competitive position is closer to a legacy sterile medical product than to a conventional branded small-molecule drug facing a patent expiration.
Who manufactures DIANEAL PD-2 now?
The Kidney Care business formerly owned by Baxter was acquired by Carlyle in 2024 and operates as Vantive. Product manufacturing and distribution should be evaluated under the applicable Vantive regulatory and commercial entities.
Does DIANEAL PD-2 have a biosimilar risk?
No. DIANEAL PD-2 is not a biologic. Biosimilar pathways do not apply. Competition would come from equivalent or alternative dialysis solutions and integrated dialysis-product suppliers.
Why is the 2.5% dextrose concentration commercially important?
The 2.5% concentration provides greater osmotic ultrafiltration than lower-dextrose solutions. It is selected for patients who require greater fluid removal, subject to clinical judgment and monitoring.
Could a generic company launch DIANEAL PD-2 without a Paragraph IV challenge?
Potentially. If no blocking patent is listed or enforceable, a competitor could pursue the applicable FDA approval pathway for an equivalent dialysis solution. The principal barriers would be formulation equivalence, sterile manufacturing, packaging, quality validation and commercial supply.
References
- U.S. Food and Drug Administration. (2024). DIANEAL PD-2 peritoneal dialysis solution prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Baxter International Inc. (2024, August 31). Baxter completes sale of Kidney Care business to Carlyle.
- Fresenius Medical Care AG. (2024). Annual report 2023.
- Baxter International Inc. (2024). Annual report 2023.
